120 related articles for article (PubMed ID: 10450539)
1. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Jastrzebska M; Torbus-Lisiecka B; Pieczul-Mróz J; Chelstowski K; Kopciewicz J; Naruszewicz M
Int J Clin Pharmacol Res; 1999; 19(1):19-25. PubMed ID: 10450539
[TBL] [Abstract][Full Text] [Related]
2. Etofibrate therapy and effect of added low-dose cholestyramine in patients with combined hyperlipidaemia.
Krüger B
Int J Clin Pharmacol Res; 1994; 14(5-6):177-83. PubMed ID: 7672874
[TBL] [Abstract][Full Text] [Related]
3. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Freyberger H; Schifferdecker E; Schatz H
Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
[TBL] [Abstract][Full Text] [Related]
4. [Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate].
Fonseca FA; Novazzi JP; Cendoroglo MS; Duarte M; Almeida Pinto LE; Rabelo LM; da Rocha Martinez TL
Arq Bras Cardiol; 1996 Jan; 66(1):33-5. PubMed ID: 8731322
[TBL] [Abstract][Full Text] [Related]
5. [Effect of ciprofibrate on the endothelial dysfunction of patients with combined dyslipidemia].
Kovács I; Tarján J; Császár A
Orv Hetil; 2001 Apr; 142(15):775-9. PubMed ID: 11367862
[TBL] [Abstract][Full Text] [Related]
6. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
Horváth M; Varsányl M; Jovanovich N; Romics L; Gerö S
Allergol Immunopathol (Madr); 1990; 18(2):95-9. PubMed ID: 2371944
[TBL] [Abstract][Full Text] [Related]
7. [Changes in serum lipids, plasma fibrinogen and other haemostatic parameters induced by ciprofibrate action in hyperlipidemic patients with and without coronary artery disease].
Espinosa RA; Rodríguez-Roa E; Nagy E; Mijares ME; Rodríguez-Larralde A; Gil A; Lundberg U; Carvajal Z; Castillo L; Arocha-Piñango CL
Invest Clin; 2006 Mar; 47(1):35-48. PubMed ID: 16562643
[TBL] [Abstract][Full Text] [Related]
8. Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary artery lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque.
Kowalski M
J Physiol Pharmacol; 2001 Aug; 52(1 Suppl 1):3-31. PubMed ID: 11795863
[TBL] [Abstract][Full Text] [Related]
9. [The new atherogenic plasma index reflects the triglyceride and HDL-cholesterol ratio, the lipoprotein particle size and the cholesterol esterification rate: changes during lipanor therapy].
Dobiásová M; Frohlich J
Vnitr Lek; 2000 Mar; 46(3):152-6. PubMed ID: 11048517
[TBL] [Abstract][Full Text] [Related]
10. [Effects of bezafibrate in the diet of hypertensive patients with dyslipidemia and hyperfibrinogenemia].
Vázquez-Chávez C; Salinas-Orozco S; Gómez-Díaz RA; Rosso-Juárez MM; Moreno-Vázquez K; Nissen-Torres T; Argüero-Sánchez R
Rev Invest Clin; 1998; 50(6):491-6. PubMed ID: 10070221
[TBL] [Abstract][Full Text] [Related]
11. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.
Wu TJ; Ou HY; Chou CW; Hsiao SH; Lin CY; Kao PC
Ann Clin Lab Sci; 2007; 37(2):158-66. PubMed ID: 17522372
[TBL] [Abstract][Full Text] [Related]
12. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
Bermúdez-Pirela V; Souki A; Cano-Ponce C; Bermúdez-Arias F; Mengual-Moreno E; Leal-Gonzalez E; Lemus-Antepaz M; de Bravo MC; de Díaz AA; de Pirela NL; Cano-Peñaloza R; Puche-Medina G; Arraiz N; Reyna-Villazmil N; Contreras F; Israili ZH; Valasco M
Am J Ther; 2007; 14(2):213-20. PubMed ID: 17414592
[TBL] [Abstract][Full Text] [Related]
13. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII.
Fincham JE; Quack G; Wülfroth P; Benadé AJ
Arzneimittelforschung; 1996 May; 46(5):519-25. PubMed ID: 8737639
[TBL] [Abstract][Full Text] [Related]
14. [Atherosclerosis treatment with etofibrate retard. New perspectives].
Degenring FH; Schatton W; Hotz W
Fortschr Med; 1983 Aug; 101(30):1391-6. PubMed ID: 6618402
[TBL] [Abstract][Full Text] [Related]
15. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study].
dos Santos JE; Loures-Vale AA; Novazzi JP; Rabelo LM; Martinez TL
Arq Bras Cardiol; 1996 Dec; 67(6):419-22. PubMed ID: 9246832
[TBL] [Abstract][Full Text] [Related]
17. [Effectiveness of etofibrate in arteriosclerosis obliterans. Pilot study in hyperlipidemic patients with arteriosclerosis obliterans].
Dembińska-Kieć A; Kostka-Trabka E; Grodzińska L; Bieroń K; Kedzior A; Basista M; Zmuda A; Trabka E; Slawiński M; Czarnecka H
Fortschr Med; 1989 Jul; 107(20):450-2. PubMed ID: 2767596
[TBL] [Abstract][Full Text] [Related]
18. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness of ciprofibrate. Open study in a Portuguese population].
Silva JM; Branco MC; Pereira M; Figueiredo H; Jesus LC; de Moura JP; Ferreira MR; Serra e Silva P
Rev Port Cardiol; 1995 Apr; 14(4):313-22, 284. PubMed ID: 7612280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
